XPhyto Initiates Infectious Disease Programs
Vancouver, Canada (March 03, 2020) – XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”), will be commencing several research and development programs related to infectious disease. These programs include in-vitro study of thin film delivery of cannabigerol (CBG) and quercetin for potential anti-bacterial and anti-viral treatments, respectively, as well as the development of point-of-care sensor-film infectious disease detection products.
Vektor is a narcotics manufacturer, importer, and research enterprise located in the Upper Swabia region of the German state of Baden-Württemberg. The company is an expert in the design, testing and manufacture of thin film drug delivery systems, including transdermal patches and sub-lingual (oral) strips. Vektor also holds a number of valid licences for import, handling and manufacturing of narcotics pursuant to EU GMP certification and other governing regulations. Vektor is permitted to develop and manufacture novel vaccine products for research and development purposes.
XPhyto’s current product development programs are focused on precision dosing of tetrahydrocannabinol (THC) and cannabidiol (CBD) using Vektor’s proprietary thin-film sub-lingual (oral) strip technology. Targeted medical conditions include serious disorders such as epilepsy and appetite regulation. Based on Vektor’s deep understanding of thin-film drug delivery systems, its current THC and CBD-focused clinical programs, and anticipated future demand for anti-viral therapeutics, XPhyto has initiated a CBG and quercetin-focused research and development program, starting with in-vitro delivery studies at its lab in Germany. Notably, CBG and quercetin, both natural compounds, have demonstrated anti-microbial properties in peer reviewed academic research. Pending successful results, the Company will evaluate clinical opportunities for further development.
“In light of the pending global coronavirus disease pandemic and anticipated long-term growing demand for novel anti-viral and anti-microbial treatments, XPhyto is moving forward with an infectious disease-related research and development program,” said Hugh Rogers, CEO of XPhyto. “XPhyto’s thinfilm drug delivery system is a platform technology capable of delivering various active therapeutic compounds for a broad range of medical conditions, including infectious disease.”
Oral thin film drug delivery, which includes the treatment of infectious disease, is a rapidly growing segment of the global healthcare and pharmaceutical industry. Transparency Market Research estimates that the global market for thin film drug manufacturing will be worth US$15.984 billion by 2024 and rising at a solid 9.0% CAGR between 2019 and 2024.
XPhyto is investigating the use of enzyme-targeted sensor-film technology for the real-time detection of infectious diseases, such as coronavirus disease (COVID-19). The goal is development of a low-cost, point-of-care, rapid detection test using senor-film technology.
Mr. Knox Henderson